Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oteseconazole for Recurrent Vulvovaginal Candidiasis (VIOLET)
NCT03562156Phase 3Completed
- Sponsor
- Mycovia Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
A Phase 3 trial of oteseconazole in recurrent vulvovaginal candidiasis (RVVC), sponsored by Mycovia Pharmaceuticals. Started Aug 2018; status: completed.
02
Drugs
oteseconazole
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT03562156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562156.